TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: STOP-AUST: The Spot Sign and Tranexamic Acid On Preventing ICH Growth - AUStralasia Trial.
Brief Summary: The aim of the study is to test if intracerebral haemorrhage (ICH) patients who have contrast extravasation on computed tomography angiography, the "spot sign", have lower rates of haematoma growth when treated with tranexamic acid within 4.5 hours of stroke onset, compared to placebo.


Options:
A: Arm Label: Tranexamic acid; Type: EXPERIMENTAL; Interventions: Drug: Tranexamic acid | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Saline 0.9% | Intervention Type: DRUG; Name: Tranexamic acid; Assigned to Arm(s): Tranexamic acid | Intervention Type: DRUG; Name: Saline 0.9%; Assigned to Arm(s): Placebo
B: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Drug: Desmopressin Injection | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal saline | Intervention Type: DRUG; Name: Desmopressin Injection; Assigned to Arm(s): Intervention | Intervention Type: DRUG; Name: Normal saline; Assigned to Arm(s): Control
C: Arm Label: Tranexamic Acid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tranexamic Acid | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Tranexamic Acid; Assigned to Arm(s): Tranexamic Acid | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Group 1-Recombinant activated factor VII; Type: ACTIVE_COMPARATOR; Interventions: Drug: recombinant activated factor VII | Arm Label: Group 2 - Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Group 3 - Observation Only Arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: recombinant activated factor VII; Assigned to Arm(s): Group 1-Recombinant activated factor VII | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Group 2 - Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation and Development of a Novel Binocular Treatment (I-BiTTM) System Using Video Clips and Interactive Games to Improve Vision in Children With Amblyopia ('Lazy Eye').
Brief Summary: The study aims to determine whether 30 minutes of treatment playing an interactive computer game weekly for 6 weeks, improves visual acuity. The game has been specially configured to ensure the amblyopic eye is preferentially stimulated and the patient wears shutter glasses which manipulate the image seen by each eye in order to provide more information to the amblyopic eye. Patients will be randomised to play the computer game using the I-BiTTM technology, play the computer game but without the I-BiTTM technology, or watch a DVD using the I-BiTTM technology.


Options:
A: Arm Label: Recommendation of Patching; Type: ACTIVE_COMPARATOR; Interventions: Other: Patching Therapy | Arm Label: Recommendation of Patching and interactive binocular treatment; Type: ACTIVE_COMPARATOR; Interventions: Other: Patching Therapy, Device: Interactive Binocular Treatment System | Intervention Type: OTHER; Name: Patching Therapy; Assigned to Arm(s): Recommendation of Patching, Recommendation of Patching and interactive binocular treatment | Intervention Type: DEVICE; Name: Interactive Binocular Treatment System; Assigned to Arm(s): Recommendation of Patching and interactive binocular treatment
B: Arm Label: I-BiTTM game; Type: EXPERIMENTAL; Interventions: Device: I-BiTTM game | Arm Label: Non-I-BiTTM game; Type: ACTIVE_COMPARATOR; Interventions: Device: Non-I-BiTTM game | Arm Label: I-BiTTM DVD; Type: EXPERIMENTAL; Interventions: Device: I-BiTTM DVD | Intervention Type: DEVICE; Name: I-BiTTM game; Assigned to Arm(s): I-BiTTM game | Intervention Type: DEVICE; Name: Non-I-BiTTM game; Assigned to Arm(s): Non-I-BiTTM game | Intervention Type: DEVICE; Name: I-BiTTM DVD; Assigned to Arm(s): I-BiTTM DVD
C: Intervention Type: DEVICE; Name: Eye patch; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: spectacles; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: atropine; Assigned to Arm(s): N/A
D: Arm Label: Binocular Computer Game Treatment; Type: EXPERIMENTAL; Interventions: Other: iPad® | Arm Label: Continued Spectacle Correction; Type: ACTIVE_COMPARATOR; Interventions: Other: Spectacle correction | Intervention Type: OTHER; Name: iPad®; Assigned to Arm(s): Binocular Computer Game Treatment | Intervention Type: OTHER; Name: Spectacle correction; Assigned to Arm(s): Continued Spectacle Correction

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation and Development of a Novel Binocular Treatment (I-BiTTM) System Using Video Clips and Interactive Games to Improve Vision in Children With Amblyopia ('Lazy Eye').
Brief Summary: The study aims to determine whether 30 minutes of treatment playing an interactive computer game weekly for 6 weeks, improves visual acuity. The game has been specially configured to ensure the amblyopic eye is preferentially stimulated and the patient wears shutter glasses which manipulate the image seen by each eye in order to provide more information to the amblyopic eye. Patients will be randomised to play the computer game using the I-BiTTM technology, play the computer game but without the I-BiTTM technology, or watch a DVD using the I-BiTTM technology.


Options:
A: Arm Label: I-BiTTM game; Type: EXPERIMENTAL; Interventions: Device: I-BiTTM game | Arm Label: Non-I-BiTTM game; Type: ACTIVE_COMPARATOR; Interventions: Device: Non-I-BiTTM game | Arm Label: I-BiTTM DVD; Type: EXPERIMENTAL; Interventions: Device: I-BiTTM DVD | Intervention Type: DEVICE; Name: I-BiTTM game; Assigned to Arm(s): I-BiTTM game | Intervention Type: DEVICE; Name: Non-I-BiTTM game; Assigned to Arm(s): Non-I-BiTTM game | Intervention Type: DEVICE; Name: I-BiTTM DVD; Assigned to Arm(s): I-BiTTM DVD
B: Arm Label: Atropine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atropine | Arm Label: Atropine plus plano; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atropine, Device: Plano Lens | Intervention Type: DRUG; Name: Atropine; Assigned to Arm(s): Atropine, Atropine plus plano | Intervention Type: DEVICE; Name: Plano Lens; Assigned to Arm(s): Atropine plus plano
C: Arm Label: Patching; Type: ACTIVE_COMPARATOR; Interventions: Device: Patching, Procedure: Near activities | Arm Label: Atropine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atropine, Procedure: Near activities | Intervention Type: DRUG; Name: Atropine; Assigned to Arm(s): Atropine | Intervention Type: DEVICE; Name: Patching; Assigned to Arm(s): Patching | Intervention Type: PROCEDURE; Name: Near activities; Assigned to Arm(s): Atropine, Patching
D: Intervention Type: DRUG; Name: Atropine; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation and Development of a Novel Binocular Treatment (I-BiTTM) System Using Video Clips and Interactive Games to Improve Vision in Children With Amblyopia ('Lazy Eye').
Brief Summary: The study aims to determine whether 30 minutes of treatment playing an interactive computer game weekly for 6 weeks, improves visual acuity. The game has been specially configured to ensure the amblyopic eye is preferentially stimulated and the patient wears shutter glasses which manipulate the image seen by each eye in order to provide more information to the amblyopic eye. Patients will be randomised to play the computer game using the I-BiTTM technology, play the computer game but without the I-BiTTM technology, or watch a DVD using the I-BiTTM technology.


Options:
A: Intervention Type: DRUG; Name: Atropine; Assigned to Arm(s): N/A
B: Arm Label: Patching; Type: ACTIVE_COMPARATOR; Interventions: Device: Eye Patch | Arm Label: Atropine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atropine | Intervention Type: DRUG; Name: Atropine; Assigned to Arm(s): Atropine | Intervention Type: DEVICE; Name: Eye Patch; Assigned to Arm(s): Patching
C: Arm Label: I-BiTTM game; Type: EXPERIMENTAL; Interventions: Device: I-BiTTM game | Arm Label: Non-I-BiTTM game; Type: ACTIVE_COMPARATOR; Interventions: Device: Non-I-BiTTM game | Arm Label: I-BiTTM DVD; Type: EXPERIMENTAL; Interventions: Device: I-BiTTM DVD | Intervention Type: DEVICE; Name: I-BiTTM game; Assigned to Arm(s): I-BiTTM game | Intervention Type: DEVICE; Name: Non-I-BiTTM game; Assigned to Arm(s): Non-I-BiTTM game | Intervention Type: DEVICE; Name: I-BiTTM DVD; Assigned to Arm(s): I-BiTTM DVD
D: Arm Label: Patching; Type: ACTIVE_COMPARATOR; Interventions: Device: Patching, Procedure: Near activities | Arm Label: Atropine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atropine, Procedure: Near activities | Intervention Type: DRUG; Name: Atropine; Assigned to Arm(s): Atropine | Intervention Type: DEVICE; Name: Patching; Assigned to Arm(s): Patching | Intervention Type: PROCEDURE; Name: Near activities; Assigned to Arm(s): Atropine, Patching

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Hypothesis: Use of Bifidobacterium animalis subsp. lactis can effectively prevent common nosocomial (gastrointestinal and respiratory) infections. Nosocomial infection will be defined as infections which develop more than 48 hours after admission and they are not present or incubating on admission

This study is a prospective, randomized, double blind, placebo- controlled parallel study in children hospitalized at Children's hospital Zagreb.

The study will investigate the effect of supplementation with the probiotic strain Bifidobacterium animalis subsp. lactis on the incidence and duration of gastrointestinal and respiratory infections.

The test product is a sachet containing 1 gram of powder. The test product will contain minimum 1 billion CFU (colony forming units) probiotic per serving.

The placebo product is an identical product except for the absence of probiotics.

The study includes an intervention period lasting the length of the hospital stay.

The study product will be consumed daily in the morning together with breakfast.

The consumption of the study products will be taken under the surveillance of the physician.

Data on infections will be diagnosed by a physician and recorded in a CRF. The incidence of infections will be analyzed based on the information recorded in the CRF.


Options:
A: Arm Label: 1 = Tested product; Type: ACTIVE_COMPARATOR; Interventions: Other: 1-Fermented dairy product containing the probiotic Lactobacillus casei DN-114 001 (Actimel®) | Arm Label: 2 = Control product; Type: SHAM_COMPARATOR; Interventions: Other: 2-Non fermented dairy product (control) | Intervention Type: OTHER; Name: 1-Fermented dairy product containing the probiotic Lactobacillus casei DN-114 001 (Actimel®); Assigned to Arm(s): 1 = Tested product | Intervention Type: OTHER; Name: 2-Non fermented dairy product (control); Assigned to Arm(s): 2 = Control product
B: Arm Label: Bifidobacterium animalis subsp. lactis; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Bifidobacterium animalis subsp. lactis | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Bifidobacterium animalis subsp. lactis; Assigned to Arm(s): Bifidobacterium animalis subsp. lactis
C: Intervention Type: DRUG; Name: Mixture of probiotic bacteria and prebiotic oligosaccharide; Assigned to Arm(s): N/A
D: Arm Label: No probiotics; Type: ACTIVE_COMPARATOR; Interventions: Other: Infant formula | Arm Label: Probiotic; Type: EXPERIMENTAL; Interventions: Other: Infant formula | Intervention Type: OTHER; Name: Infant formula; Assigned to Arm(s): No probiotics | Intervention Type: OTHER; Name: Infant formula; Assigned to Arm(s): Probiotic

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Transfusion of Prematures (TOP) Trial: Does a Liberal Red Blood Cell Transfusion Strategy Improve Neurologically-Intact Survival of Extremely-Low-Birth-Weight Infants as Compared to a Restrictive Strategy?
Brief Summary: The objective of the TOP trial is to determine whether higher hemoglobin thresholds for transfusing ELBW infants resulting in higher hemoglobin levels lead to improvement in the primary outcome of survival and rates of neurodevelopmental impairment (NDI) at 22-26 months of age, using standardized assessments by Bayley.


Options:
A: Arm Label: Liberal; Type: EXPERIMENTAL; Interventions: Drug: red blood cell transfusion trigger | Arm Label: Restrictive; Type: ACTIVE_COMPARATOR; Interventions: Drug: red blood cell transfusion trigger | Intervention Type: DRUG; Name: red blood cell transfusion trigger; Assigned to Arm(s): Liberal, Restrictive
B: Arm Label: Restrictive Red blood cell Transfusion; Type: EXPERIMENTAL; Interventions: Other: Red blood cell Transfusion | Arm Label: Liberal Red blood Cell Transfusion; Type: ACTIVE_COMPARATOR; Interventions: Other: Red blood cell Transfusion | Intervention Type: OTHER; Name: Red blood cell Transfusion; Assigned to Arm(s): Liberal Red blood Cell Transfusion, Restrictive Red blood cell Transfusion
C: Arm Label: Low Threshold Transfusion; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Restricted red cell transfusion | Arm Label: High Threshold Transfusion; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Liberal Cell Transfusion | Intervention Type: PROCEDURE; Name: Liberal Cell Transfusion; Assigned to Arm(s): High Threshold Transfusion | Intervention Type: PROCEDURE; Name: Restricted red cell transfusion; Assigned to Arm(s): Low Threshold Transfusion
D: Arm Label: Liberal; Type: ACTIVE_COMPARATOR; Interventions: Other: Liberal transfusion threshold | Arm Label: Restrictive; Type: ACTIVE_COMPARATOR; Interventions: Other: Restrictive transfusion threshold | Intervention Type: OTHER; Name: Restrictive transfusion threshold; Assigned to Arm(s): Restrictive | Intervention Type: OTHER; Name: Liberal transfusion threshold; Assigned to Arm(s): Liberal

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Transfusion of Prematures (TOP) Trial: Does a Liberal Red Blood Cell Transfusion Strategy Improve Neurologically-Intact Survival of Extremely-Low-Birth-Weight Infants as Compared to a Restrictive Strategy?
Brief Summary: The objective of the TOP trial is to determine whether higher hemoglobin thresholds for transfusing ELBW infants resulting in higher hemoglobin levels lead to improvement in the primary outcome of survival and rates of neurodevelopmental impairment (NDI) at 22-26 months of age, using standardized assessments by Bayley.


Options:
A: Arm Label: Infant Blood; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Drawing admission labs from infant blood | Arm Label: Cord Blood; Type: EXPERIMENTAL; Interventions: Procedure: Drawing admission labs from cord blood | Intervention Type: PROCEDURE; Name: Drawing admission labs from cord blood; Assigned to Arm(s): Cord Blood | Intervention Type: PROCEDURE; Name: Drawing admission labs from infant blood; Assigned to Arm(s): Infant Blood
B: Arm Label: Darbepoetin; Type: EXPERIMENTAL; Interventions: Drug: Darbepoetin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Darbepoetin; Assigned to Arm(s): Darbepoetin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: "liberal" transfusion triggers; Type: EXPERIMENTAL; Interventions: Other: red blood cell transfusion | Arm Label: "restrictive" transfusion triggers; Type: ACTIVE_COMPARATOR; Interventions: Other: red blood cell transfusion | Intervention Type: OTHER; Name: red blood cell transfusion; Assigned to Arm(s): "liberal" transfusion triggers | Intervention Type: OTHER; Name: red blood cell transfusion; Assigned to Arm(s): "restrictive" transfusion triggers
D: Arm Label: Low Threshold Transfusion; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Restricted red cell transfusion | Arm Label: High Threshold Transfusion; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Liberal Cell Transfusion | Intervention Type: PROCEDURE; Name: Liberal Cell Transfusion; Assigned to Arm(s): High Threshold Transfusion | Intervention Type: PROCEDURE; Name: Restricted red cell transfusion; Assigned to Arm(s): Low Threshold Transfusion

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess Cardiovascular Outcomes Following Treatment With MK-3102 in Subjects With Type 2 Diabetes Mellitus
Brief Summary: The purpose of this study is to evaluate the cardiovascular (CV) safety profile of omarigliptin in participants with type 2 diabetes mellitus (T2DM). The primary hypothesis is that treatment with omarigliptin 25 mg once weekly is non-inferior to treatment with placebo and active comparators across the omarigliptin program with regard to the risk of developing a confirmed event in the primary CV composite endpoint.


Options:
A: Arm Label: Liraglutid; Type: ACTIVE_COMPARATOR; Interventions: Drug: liraglutide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Liraglutid | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Canagliflozin (JNJ-28431754) 100 mg; Type: EXPERIMENTAL; Interventions: Drug: Canagliflozin (JNJ-28431754) 100 mg | Arm Label: Canagliflozin (JNJ-28431754) 300 mg; Type: EXPERIMENTAL; Interventions: Drug: Canagliflozin (JNJ-28431754) 300 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Canagliflozin (JNJ-28431754) 100 mg; Assigned to Arm(s): Canagliflozin (JNJ-28431754) 100 mg | Intervention Type: DRUG; Name: Canagliflozin (JNJ-28431754) 300 mg; Assigned to Arm(s): Canagliflozin (JNJ-28431754) 300 mg
C: Arm Label: Empagliflozin; Type: EXPERIMENTAL; Interventions: Drug: Empagliflozin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Empagliflozin; Assigned to Arm(s): Empagliflozin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Omarigliptin; Type: EXPERIMENTAL; Interventions: Drug: Omarigliptin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Omarigliptin; Assigned to Arm(s): Omarigliptin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection
Brief Summary: There has been an alarming increase in the incidence and severity of Clostridium difficile infection (CDI) in North America over the past decade. Relapsing infection is a common problem in patients treated for CDI, often requiring prolonged and expensive courses of oral vancomycin with limited alternative treatment options. This study will determine if fecal microbiota transplantation, which involves administering fecal flora from a healthy stool donor to a patient with relapsing CDI, is an effective and safe treatment.


Options:
A: Arm Label: Multiple-infusion FMT; Type: EXPERIMENTAL; Interventions: Drug: Vancomycin (before randomization), Biological: multiple-infusion FMT | Arm Label: Single-infusion FMT; Type: ACTIVE_COMPARATOR; Interventions: Biological: Single-infusion FMT, Drug: Vancomycin (before randomization) | Intervention Type: BIOLOGICAL; Name: Single-infusion FMT; Assigned to Arm(s): Single-infusion FMT | Intervention Type: DRUG; Name: Vancomycin (before randomization); Assigned to Arm(s): Multiple-infusion FMT, Single-infusion FMT | Intervention Type: BIOLOGICAL; Name: multiple-infusion FMT; Assigned to Arm(s): Multiple-infusion FMT
B: Arm Label: Fecal transplantation; Type: EXPERIMENTAL; Interventions: Biological: Fecal transplantation | Arm Label: Placebo fecal transplantation; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo fecal transplant | Intervention Type: BIOLOGICAL; Name: Fecal transplantation; Assigned to Arm(s): Fecal transplantation | Intervention Type: OTHER; Name: Placebo fecal transplant; Assigned to Arm(s): Placebo fecal transplantation
C: Arm Label: Fecal Microbiota Transplantation; Type: ACTIVE_COMPARATOR; Interventions: Biological: Fecal Microbiota Transplantation | Arm Label: Sham Fecal Microbiota Transplantation; Type: SHAM_COMPARATOR; Interventions: Biological: Sham Fecal Microbiota Transplantation | Intervention Type: BIOLOGICAL; Name: Fecal Microbiota Transplantation; Assigned to Arm(s): Fecal Microbiota Transplantation | Intervention Type: BIOLOGICAL; Name: Sham Fecal Microbiota Transplantation; Assigned to Arm(s): Sham Fecal Microbiota Transplantation
D: Arm Label: Colonoscopy; Type: EXPERIMENTAL; Interventions: Drug: Fecal Microbiota Transplant (FMT) | Arm Label: Nasogastric Tube (NGT); Type: EXPERIMENTAL; Interventions: Drug: Fecal Microbiota Transplant (FMT) | Intervention Type: DRUG; Name: Fecal Microbiota Transplant (FMT); Assigned to Arm(s): Colonoscopy, Nasogastric Tube (NGT)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection
Brief Summary: There has been an alarming increase in the incidence and severity of Clostridium difficile infection (CDI) in North America over the past decade. Relapsing infection is a common problem in patients treated for CDI, often requiring prolonged and expensive courses of oral vancomycin with limited alternative treatment options. This study will determine if fecal microbiota transplantation, which involves administering fecal flora from a healthy stool donor to a patient with relapsing CDI, is an effective and safe treatment.


Options:
A: Arm Label: Fresh FMT; Type: EXPERIMENTAL; Interventions: Biological: Fresh FMT | Arm Label: Frozen-and-Thawed FMT; Type: EXPERIMENTAL; Interventions: Biological: Frozen-and-Thawed FMT | Intervention Type: BIOLOGICAL; Name: Fresh FMT; Assigned to Arm(s): Fresh FMT | Intervention Type: BIOLOGICAL; Name: Frozen-and-Thawed FMT; Assigned to Arm(s): Frozen-and-Thawed FMT
B: Arm Label: co-transplantation of FMT and pectin; Type: EXPERIMENTAL; Interventions: Other: co-transplantation of FMT and pectin | Arm Label: single fecal microbiota transplantation; Type: ACTIVE_COMPARATOR; Interventions: Other: single fecal microbiota transplantation | Arm Label: give pectin 20g/d; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: pure give pectin 20g/d for five days | Intervention Type: OTHER; Name: co-transplantation of FMT and pectin; Assigned to Arm(s): co-transplantation of FMT and pectin | Intervention Type: OTHER; Name: single fecal microbiota transplantation; Assigned to Arm(s): single fecal microbiota transplantation | Intervention Type: DIETARY_SUPPLEMENT; Name: pure give pectin 20g/d for five days; Assigned to Arm(s): give pectin 20g/d
C: Arm Label: Colonoscopy; Type: EXPERIMENTAL; Interventions: Drug: Fecal Microbiota Transplant (FMT) | Arm Label: Nasogastric Tube (NGT); Type: EXPERIMENTAL; Interventions: Drug: Fecal Microbiota Transplant (FMT) | Intervention Type: DRUG; Name: Fecal Microbiota Transplant (FMT); Assigned to Arm(s): Colonoscopy, Nasogastric Tube (NGT)
D: Arm Label: Fecal Microbiota Transplantation; Type: ACTIVE_COMPARATOR; Interventions: Biological: Fecal Microbiota Transplantation | Arm Label: Sham Fecal Microbiota Transplantation; Type: SHAM_COMPARATOR; Interventions: Biological: Sham Fecal Microbiota Transplantation | Intervention Type: BIOLOGICAL; Name: Fecal Microbiota Transplantation; Assigned to Arm(s): Fecal Microbiota Transplantation | Intervention Type: BIOLOGICAL; Name: Sham Fecal Microbiota Transplantation; Assigned to Arm(s): Sham Fecal Microbiota Transplantation

Answer: D